Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2022 | 3 |
2024 | 1 |
Search Results
5 results
Results by year
Filters applied: . Clear all
Page 1
Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling.
Sci Adv. 2024 Jan 19;10(3):eadi2012. doi: 10.1126/sciadv.adi2012. Epub 2024 Jan 19.
Sci Adv. 2024.
PMID: 38241371
Free PMC article.
Inhibition of Melanoma Cell-Intrinsic Tim-3 Stimulates MAPK-Dependent Tumorigenesis.
Schatton T, Itoh Y, Martins C, Rasbach E, Singh P, Silva M, Mucciarone K, Heppt MV, Geddes-Sweeney J, Stewart K, Brandenburg A, Liang J, Dimitroff CJ, Mihm MC, Landsberg J, Schlapbach C, Lian CG, Murphy GF, Kupper TS, Ramsey MR, Barthel SR.
Schatton T, et al.
Cancer Res. 2022 Oct 17;82(20):3774-3784. doi: 10.1158/0008-5472.CAN-22-0970.
Cancer Res. 2022.
PMID: 35980306
Free PMC article.
Item in Clipboard
Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity.
Ordikhani F, Uehara M, Kasinath V, Dai L, Eskandari SK, Bahmani B, Yonar M, Azzi JR, Haik Y, Sage PT, Murphy GF, Annabi N, Schatton T, Guleria I, Abdi R.
Ordikhani F, et al.
JCI Insight. 2018 Oct 18;3(20):e122700. doi: 10.1172/jci.insight.122700.
JCI Insight. 2018.
PMID: 30333312
Free PMC article.
Item in Clipboard
Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells.
Martins C, Silva M, Rasbach E, Singh P, Itoh Y, Williams JB, Statham E, Meurer A, Martinez DV, Brandenburg A, Heppt MV, Barthel SR, Schatton T.
Martins C, et al.
Sci Rep. 2022 Jul 21;12(1):12491. doi: 10.1038/s41598-022-16776-1.
Sci Rep. 2022.
PMID: 35864188
Free PMC article.
Item in Clipboard
Comparative efficacy analysis identifies immune checkpoint blockade as a new survival benchmark in advanced cutaneous squamous cell carcinoma.
Petzold A, Steeb T, Wessely A, Schatton T, Berking C, Heppt MV.
Petzold A, et al.
Eur J Cancer. 2022 Jul;170:42-53. doi: 10.1016/j.ejca.2022.03.035. Epub 2022 May 17.
Eur J Cancer. 2022.
PMID: 35594611
Item in Clipboard
Cite
Cite